93 related articles for article (PubMed ID: 22107083)
1. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.
Fernández O; Arroyo R; Martínez-Yélamos S; Marco M; Merino JA; Muñoz D; Merino E; Roque A;
PLoS One; 2016; 11(8):e0160313. PubMed ID: 27526201
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab: A new treatment for relapsing remitting multiple sclerosis.
Hutchinson M
Ther Clin Risk Manag; 2007 Jun; 3(2):259-68. PubMed ID: 18360634
[TBL] [Abstract][Full Text] [Related]
4. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Iaffaldano P; Viterbo RG; Paolicelli D; Lucchese G; Portaccio E; Goretti B; Direnzo V; D'Onghia M; Zoccolella S; Amato MP; Trojano M
PLoS One; 2012; 7(4):e35843. PubMed ID: 22558238
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R
PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120
[TBL] [Abstract][Full Text] [Related]
6. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis.
Naughton M; Moffat J; Eleftheriadis G; de la Vega Gallardo N; Young A; Falconer J; Hawkins K; Pearson B; Perbal B; Hogan A; Moynagh P; Loveless S; Robertson NP; Gran B; Kee R; Hughes S; McDonnell G; Howell O; Fitzgerald DC
J Neuroinflammation; 2020 Nov; 17(1):349. PubMed ID: 33222687
[TBL] [Abstract][Full Text] [Related]
7. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
Klawiter EC; Cross AH; Naismith RT
Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475
[TBL] [Abstract][Full Text] [Related]
8. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.
Carvajal R; Zabalza A; Carbonell-Mirabent P; Martínez-Gómez X; Esperalba J; Pappolla A; Rando A; Cobo-Calvo A; Tur C; Rodriguez M; Río J; Comabella M; Castilló J; Rodrigo-Pendás JÁ; Braga N; Mongay-Ochoa N; Guío-Sánchez C; Vidal-Jordana Á; Arrambide G; Rodríguez-Acevedo B; Midaglia L; Borras-Bermejo B; Galán I; Sastre-Garriga J; Montalban X; Otero-Romero S; Tintoré M
JAMA Netw Open; 2024 Apr; 7(4):e246345. PubMed ID: 38607624
[TBL] [Abstract][Full Text] [Related]
9. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.
Benešová Y; Tvaroh A
Ther Adv Neurol Disord; 2017 Jan; 10(1):18-32. PubMed ID: 28450892
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta for treatment of rheumatoid arthritis?
van Holten J; Plater-Zyberk C; Tak PP
Arthritis Res; 2002; 4(6):346-52. PubMed ID: 12453310
[TBL] [Abstract][Full Text] [Related]
11. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
Filippi M; Grimaldi L; Conte A; Totaro R; Valente MR; Malucchi S; Granella F; Cordioli C; Brescia Morra V; Zanetta C; Perini D; Santoni L;
J Neurol; 2024 Jan; 271(1):340-354. PubMed ID: 37715789
[TBL] [Abstract][Full Text] [Related]
12. Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis.
Kaufmann M; Evans H; Schaupp AL; Engler JB; Kaur G; Willing A; Kursawe N; Schubert C; Attfield KE; Fugger L; Friese MA
Med; 2021 Mar; 2(3):296-312.e8. PubMed ID: 33748804
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Interferon Beta and Natalizumab on miR-20b Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Potentially Mediated by Modulation of the Jak-STAT Signaling Pathway: A Case-control Study.
Jafari Harandi A; Mirzaee Sedigh A; Ataei M; Bayrami S; Esmaeilzadeh E; Sanati MH
Iran J Immunol; 2024 May; 21(2):. PubMed ID: 38761094
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Spelman T; Kalincik T; Jokubaitis V; Zhang A; Pellegrini F; Wiendl H; Belachew S; Hyde R; Verheul F; Lugaresi A; Havrdová E; Horáková D; Grammond P; Duquette P; Prat A; Iuliano G; Terzi M; Izquierdo G; Hupperts RM; Boz C; Pucci E; Giuliani G; Sola P; Spitaleri DL; Lechner-Scott J; Bergamaschi R; Grand'Maison F; Granella F; Kappos L; Trojano M; Butzkueven H
Neurol Clin Pract; 2016 Apr; 6(2):102-115. PubMed ID: 27104064
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of brain volume measures in multiple sclerosis.
De Stefano N; Airas L; Grigoriadis N; Mattle HP; O'Riordan J; Oreja-Guevara C; Sellebjerg F; Stankoff B; Walczak A; Wiendl H; Kieseier BC
CNS Drugs; 2014 Feb; 28(2):147-56. PubMed ID: 24446248
[TBL] [Abstract][Full Text] [Related]
16. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
17. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
19. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Kappos L; Radue EW; Comi G; Montalban X; Butzkueven H; Wiendl H; Giovannoni G; Hartung HP; Derfuss T; Naegelin Y; Sprenger T; Mueller-Lenke N; Griffiths S; von Rosenstiel P; Gottschalk R; Zhang Y; Dahlke F; Tomic D;
Neurology; 2015 Jul; 85(1):29-39. PubMed ID: 26024899
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
